Roche's Gazyva Breaks New Ground in Lupus
Roche's Gazyva could be heading for broader use in the potentially life-threatening autoimmune disorder after clearing a phase 3 trial.
Already approved for lupus nephritis, Gazyva achieved its main objective in the ALLEGORY trial, increasing the proportion of patients showing a four-point or greater improvement on the SLE Responder Index 4 (SRI-4) scale at 52 weeks, compared to placebo, when added to standard therapy.
- Gazyva is an anti-CD20 antibody.
- The drug could have broad utility in systemic lupus erythematosus (SLE), affecting around 3.4 million people worldwide.
The results suggest that Gazyva could become the first drug in the class for the disease.
Author's summary: Gazyva shows promise in treating lupus.